Search is Powered by Google
Multiple Sclerosis News

Respite Care Investment Needs Close Scrutiny, UK

Main Category: Multiple Sclerosis
Also Included In: Caregivers / Homecare
Article Date: 12 Jun 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The Government has announced a new National Strategy for Carers, which promises to double the amount spent on respite care over two years.

Chris Evans of the MS Society, who has responsibility for the charity's four respite centres, said that any new investment in respite care was always welcome but also urged caution.

He added: "The strategy is a step forward for carers and an extra £150million investment in respite care sounds good, but comes with the assumption that the current system is working well.

"To double the current spend suggests the initial £150million is already being used to maximum effect but we are constantly contacted by those who care for people with MS and told that isn't the case."

"We need to investigate the detail of the strategy and find out how much of the new investment will actually end up in the hands of those who need it most."

MS Society




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
New Data Show Patients Using AVONEX Reported Less Sick Leave And Short-Term Disability Costs
04 Jun 2008
Results from an analysis assessing the differences in health benefits costs (HBCs) and lost time among employees suffering from multiple sclerosis (MS) being treated with injectable disease modifying therapies (DMTs) were...


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

An MS Drug Back on the Market image An MS Drug Back on the Market

After being suspended from the market for safety reasons, natalizumab is again available for the treatment of multiple sclerosis. Safeguards are in place because of a small risk in developing a serious brain infection. Should you consider taking this drug...

View more videos...